Karen Waetjen
Karen Waetjen is director, GCP/GLP Compliance, Amgen.
Articles
Collaborative Efforts Address Key Data Integrity Challenges
Ganapathy Mohan;Christopher Turner ;Dennis O’Connor ;Lisa Fink ;Thomas Purdue ;Jeffrey Beebie;Kerri Robles ;Karen Waetjen
March 16th 2021Maintaining a quality culture across the diverse functions in a bio/pharmaceutical company is difficult. Representatives of the Quality Coordinating Committee of IQ Consortium report on collaborative efforts to address data integrity and the modernization of FDA’s good laboratory practice regulations.
Latest Updated Articles
Published: September 11th 2024 | Updated: September 18th 2024
CPHI Pharma Award Finalists Announced for 2024
Published: March 27th 2024 | Updated: June 28th 2024
AbbVie Acquires Landos Biopharma and Gets Full FDA Nod for ADC Product
Published: December 9th 2024 | Updated: December 22nd 2024
Recap Key Industry Trends for Viral Clearance and NGS
Published: December 7th 2024 | Updated: December 22nd 2024
Enhancing Quality Through Training
Published: July 20th 2020 | Updated: December 22nd 2024
Contact BioPharm International Editors
Published: July 19th 2020 | Updated: December 22nd 2024
Editorial Information: BioPharm International Submission Guidelines and Editorial Calendars
